Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Thomas T. Kawabata"'
Autor:
Hisashi Yamanaka, Eric Mortensen, Kevin L. Winthrop, Hernan Valdez, R. Riese, Sriram Krishnaswami, Robert Chew, Thomas T. Kawabata
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
The reactivation of varicella zoster virus (VZV), also known as herpes zoster (HZ) or shingles, is of substantial public health importance, as up to one-third of adults in the US will develop HZ within their lifetime (1–4). Nearly 100% of individua
Autor:
Marjorie Buonanno, Kim A. Papp, Hernan Valdez, J. Harness, Thomas T. Kawabata, Bruce Strober, Richard G. Langley, Robert Wolk, Alan Menter, Huaming Tan, James D. Clark
Publikováno v:
British Journal of Dermatology. 169:992-999
SummaryBackground The Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210). Objectives To report haematology data from the phase IIb trial, given the importance of J
Publikováno v:
Journal of Immunotoxicology. 11:110-115
Evidence suggests that bio-activation of drugs to generate chemically reactive metabolites (RM) that act as haptens to form immunogenic protein conjugates may be an important cause of immune-mediated drug hypersensitivity reactions (IDHR). Although m
Autor:
Ellen W. Evans, Thomas T. Kawabata
Publikováno v:
Toxicologic Pathology. 40:288-293
The ICH S8 immunotoxicity testing guideline for human pharmaceuticals was published in 2006 and was intended to provide guidance for assessing the immunotoxicity potential of low-molecular-weight drugs that are not intended to alter the immune system
Autor:
Dolca Thomas, Martin Rowe, Cris Kamperschroer, James L. Weaver, Fred Wang, Helen G. Haggerty, Thomas T. Kawabata
Publikováno v:
Journal of Immunotoxicology. 9:121-127
Epstein-Barr virus (EBV)-associated lymphomas are a known risk for immunosuppressed individuals. Non-clinical methods to determine the potential of new immunomodulatory compounds to produce EBV-associated lymphomas (hazard identification) have not be
Autor:
Mark Collinge, Cris Kamperschroer, Susan Cole, Thomas T. Kawabata, Carol B. Donovan, Patricia A. Schneider
Publikováno v:
Journal of Immunotoxicology. 7:357-366
Preclinical immunotoxicity assessments may be performed during pharmaceutical drug development in order to identify potential cause for concern prior to use in the clinic. The in vivo T-dependent antibody response (TDAR) is widely used in this regard
Autor:
Curtis Maier, James Green, Holly W. Smith, Dan Wierda, Gopi Shankar, Danuta J. Herzyk, Inge A. Ivens, Shalini Gupta, Leslie Abad, Lakshmi Amaravadi, Bonita Rup, Thomas Gelzleichter, Peter Thomas, Christopher Hurst, Rafael A. Ponce, Elizabeth R. Gore, Thomas T. Kawabata, Barbara Mounho
Publikováno v:
Regulatory Toxicology and Pharmacology. 54:164-182
An evaluation of potential antibody formation to biologic therapeutics during the course of nonclinical safety studies and its impact on the toxicity profile is expected under current regulatory guidance and is accepted standard practice. However, ap
Autor:
Deborah Finco-Kent, Nicholas Pullen, Thomas T. Kawabata, F Clemo, D Carter, P Syntin, E Molloy, S Zhao, S Sreckovic, William J. Reagan
Publikováno v:
British Journal of Pharmacology. 157:281-293
Background and purpose: The adhesion molecule mucosal addressin cell adhesion molecule (MAdCAM) plays an essential role in the recruitment of lymphocytes to specialized high endothelial venules of the gastrointestinal tract and in their excessive tis
Autor:
Daniel Wierda, Leigh Ann Burns-Naas, Herve Lebrec, Ian S Gourley, Kenneth L. Hastings, Ellen W. Evans, Danuta J. Herzyk, Joseph R. Piccotti, Thomas T. Kawabata
Publikováno v:
Journal of Immunotoxicology. 6:1-10
The number of anti-inflammatory and immunomodulatory drugs being developed in the pharmaceutical industry has increased considerably in the past decade. This increase in research and development has been paralleled by questions from both regulatory a
Autor:
Thomas T. Kawabata, Eric Wakshull, Susan M. Richards, Steven J. Swanson, Vijay Jethwa, Elizabeth Shores, Stephen R. Indelicato, Anthony Mire-Sluis, Shalini Gupta, Bonita Rup, Marian Kelley
Publikováno v:
Journal of Immunological Methods. 321:1-18
The administration of biological therapeutics can evoke some level of immune response to the drug product in the receiving subjects. An immune response comprised of neutralizing antibodies can lead to loss of efficacy or potentially more serious clin